Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Eyepoint Pharmaceuticals Inc (EYPT)

Eyepoint Pharmaceuticals Inc (EYPT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 494,820
  • Shares Outstanding, K 68,251
  • Annual Sales, $ 46,020 K
  • Annual Income, $ -70,800 K
  • EBIT $ -117 M
  • EBITDA $ -117 M
  • 60-Month Beta 1.46
  • Price/Sales 10.53
  • Price/Cash Flow N/A
  • Price/Book 1.74

Options Overview Details

View History
  • Implied Volatility 83.94% ( -2.85%)
  • Historical Volatility 74.97%
  • IV Percentile 35%
  • IV Rank 42.12%
  • IV High 175.08% on 04/18/24
  • IV Low 17.61% on 07/18/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 127
  • Volume Avg (30-Day) 261
  • Put/Call OI Ratio 0.52
  • Today's Open Interest 9,963
  • Open Int (30-Day) 12,877

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.43
  • Number of Estimates 4
  • High Estimate -0.31
  • Low Estimate -0.53
  • Prior Year -0.33
  • Growth Rate Est. (year over year) -30.30%

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.90 +6.23%
on 12/20/24
9.61 -23.73%
on 11/25/24
-1.62 (-18.10%)
since 11/22/24
3-Month
6.90 +6.23%
on 12/20/24
13.98 -47.59%
on 10/28/24
-1.01 (-12.11%)
since 09/24/24
52-Week
6.90 +6.23%
on 12/20/24
30.99 -76.35%
on 02/08/24
-15.25 (-67.54%)
since 12/22/23

Most Recent Stories

More News
EyePoint to Present at the 43rd Annual J.P. Morgan Healthcare Conference

EYPT : 7.33 (+1.10%)
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

EYPT : 7.33 (+1.10%)
EyePoint Pharmaceuticals Doses First Patient in Phase 3 LUCIA Trial for DURAVYU in Wet AMD

EyePoint Pharmaceuticals initiates LUCIA trial for DURAVYU, evaluating efficacy in wet AMD with data expected in 2026.Quiver AI SummaryEyePoint Pharmaceuticals announced that the first patient has been...

EYPT : 7.33 (+1.10%)
EyePoint Announces First Patient Dosed in Second Global Phase 3 LUCIA Clinical Trial of DURAVYU™ for the Treatment of Wet Age-Related Macular Degeneration

EYPT : 7.33 (+1.10%)
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

EYPT : 7.33 (+1.10%)
EyePoint Pharmaceuticals: Q3 Earnings Snapshot

EyePoint Pharmaceuticals: Q3 Earnings Snapshot

EYPT : 7.33 (+1.10%)
EyePoint Pharmaceuticals Reports Third Quarter 2024 Financial Results and Highlights Recent Corporate Developments

EYPT : 7.33 (+1.10%)
EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences

EYPT : 7.33 (+1.10%)
EyePoint Pharmaceuticals Announces Closing of Upsized Public Offering and Full Exercise of Option to Purchase Additional Shares

EYPT : 7.33 (+1.10%)
EyePoint Pharmaceuticals Announces Pricing of Upsized Public Offering

EYPT : 7.33 (+1.10%)

Business Summary

EyePoint Pharmaceuticals Inc. operates as a biopharmaceutical company. It engaged in the development of drug devices to treat debilitating diseases of the eye disorders and other chronic conditions. The company's product candidate consists of DEXYCU(TM). EyePoint Pharmaceuticals Inc., formerly known...

See More

Key Turning Points

3rd Resistance Point 7.70
2nd Resistance Point 7.52
1st Resistance Point 7.43
Last Price 7.33
1st Support Level 7.16
2nd Support Level 6.98
3rd Support Level 6.89

See More

52-Week High 30.99
Fibonacci 61.8% 21.79
Fibonacci 50% 18.94
Fibonacci 38.2% 16.10
Last Price 7.33
52-Week Low 6.90

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar